FDA Approves Bayer Blood Thinner Asundexian for Stroke Prevention
Sunharbo becomes the first Factor XIa inhibitor cleared in the United States to reduce repeat stroke risk.
By Giovanni Sapere
2 min readWritten with AI support · Reviewed and approved by: Letizia Giugliano

The US Food and Drug Administration has approved Bayer's once-daily oral drug asundexian, sold under the brand name Sunharbo, to prevent recurrent strokes in high-risk patients. Prescribed alongside standard antiplatelet therapy, the therapeutic innovation offers a new biological pathway to protect patients who have suffered a serious vascular blockage or a transient mini stroke.
Targeting Factor XIa to control clotting
The regulatory decision follows positive results from a global Phase 3 clinical study, as reported by New Atlas. Developed by German healthcare company Bayer, the drug represents a breakthrough medical innovation that targets a different biological mechanism than existing treatments. Most standard anticoagulants block Factor Xa, but this pharmaceutical invention instead stops Factor XIa (FXIa).
Factor XIa plays a direct role in pathological thrombus growth and vessel blockage. By inhibiting this specific enzyme, Sunharbo becomes the first approved medication in a new class of Factor XIa inhibitors worldwide, providing medical teams with an alternative approach to preventing dangerous blood clots.
“For those who survive a stroke, the risk of another potentially devastating event is highest in the days and weeks after the initial event, and that risk persists over time.”
— Dr. Ashkan Shoamanesh, Senior Scientist at Population Health Research Institute
The threat of recurring vascular events
Nearly 800,000 people in the United States suffer a stroke every year, and vascular blockage remains one of the leading causes of death worldwide. Patients who survive an initial episode face high rates of recurrence. Clinical data shows that one in five survivors experiences a secondary event within five years, which often brings greater physical impairment or higher mortality than the first episode.
Because secondary events present an enduring hazard, post-stroke management requires sustained preventive treatment. Asundexian was evaluated specifically to reduce this risk in patients receiving antiplatelet drugs.
Post-stroke care and ongoing protection
The critical danger period begins immediately after the first event. "For those who survive a stroke, the risk of another potentially devastating event is highest in the days and weeks after the initial event, and that risk persists over time," said Dr. Ashkan Shoamanesh, a senior scientist at the Population Health Research Institute, a joint institute of Hamilton Health Sciences and McMaster University in Ontario.
Marking a significant milestone in patent news, the commercial release of asundexian, supported by a vital patent, adds new intellectual property to stroke prevention, expanding treatment options beyond traditional Factor Xa inhibitors as clinicians work to improve long-term outcomes for survivors.
Read also on The Patent: Hybrid Light Technique Tracks Deep Blood Flow Inside Living Tissue · Stanford Brain Connectome Map Predicts Alzheimer Risk 12 Years Early
An article by the newsroom of The Patent ®, written with the support of artificial intelligence from sources chosen by the newsroom. Review, corrections and approval for publication: Letizia Giugliano. Publisher responsible: WitUp Ltd.



